We similarly observed decreased expression of tumor cell VEGFR2 after one cycle of chemotherapy in patients pre-treated with sunitinib as well as bevacizumab proving that both drugs exert anti-angiogenic effects through inactivation of the VEGFR2 receptor on tumor cells. This evidence concerns the gene KDR and neoplasm.